These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 11365806)
1. Another expensive drug for your cocktail. Gilden D GMHC Treat Issues; 1998 Sep; 12(9):3-6. PubMed ID: 11365806 [TBL] [Abstract][Full Text] [Related]
2. FDA approves efavirenz. Food and Drug Administration. Highleyman L BETA; 1998 Oct; ():3. PubMed ID: 11365987 [TBL] [Abstract][Full Text] [Related]
3. FDA approves Sustiva (efavirenz) capsules, first once-daily anti-HIV drug. Food and Drug Administration. Res Initiat Treat Action; 1998 Oct; 4(6):13-4. PubMed ID: 11365915 [TBL] [Abstract][Full Text] [Related]
4. Efavirenz (Sustiva) receives FDA approval. Food and Drug Administration. Proj Inf Perspect; 1998 Dec; (26):11. PubMed ID: 11366487 [TBL] [Abstract][Full Text] [Related]
5. Efavirenz (SUSTIVA) approved. James JS AIDS Treat News; 1998 Oct; (No 304):1-4. PubMed ID: 11365862 [TBL] [Abstract][Full Text] [Related]
6. New drug approved. AIDS Policy Law; 1998 Oct; 13(18):12. PubMed ID: 11365934 [TBL] [Abstract][Full Text] [Related]
7. Sustiva (efavirenz) is approved. Vazquez E Posit Aware; 1998; 9(6):17. PubMed ID: 11366471 [TBL] [Abstract][Full Text] [Related]
8. [FDA approval of the first HIV anti-retroviral from DuPont-Pharma: SUSTIVA (efavirenz). SUSTIVA should be associated with other anti-retrovirals and could be considered a new alternative first line treatment]. Allerg Immunol (Paris); 1998 Oct; 30(8):268-70. PubMed ID: 9846197 [No Abstract] [Full Text] [Related]
9. Efavirenz (Sustiva) on fast-track for FDA accelerated approval. Food and Drug Administration. Baker R BETA; 1998 Jul; ():9. PubMed ID: 11365571 [TBL] [Abstract][Full Text] [Related]
10. Efavirenz (Sustiva) may equal or exceed protease inhibitor in initial antiretroviral combination. James JS AIDS Treat News; 1998 Jul; (No 299):1-3. PubMed ID: 11365599 [TBL] [Abstract][Full Text] [Related]
11. Now approved: Sustiva in combination offers patients a new first-line therapy. Fac Notes (New Orleans La); 1998; 10(6):10. PubMed ID: 11366140 [TBL] [Abstract][Full Text] [Related]